Dinutuximab: First Global Approval

  title={Dinutuximab: First Global Approval},
  author={Sohita Dhillon},
United Therapeutics Corporation and the National Cancer Institute are developing dinutuximab (Unituxin™; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma. GD2 is a glycolipid found on the surface of tumour cells, which is overexpressed in neuroblastoma. Dinutuximab, an IgG1 human/mouse chimeric switch variant of murine monoclonal antibody 14G2a, binds to GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. The US… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 16 extracted citations


Publications referenced by this paper.
Showing 1-10 of 22 references

and Drug Administration

  • US Foo
  • Dinutuximab. 2015. http:// www.fda.gov/Drugs…
  • 2015
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…